Classical and emerging therapeutic targets for hypertension, including the aldosterone pathway, vaccines, and the gastrointestinal microbiome, offer potential utility for blood pressure management.
This review outlines emerging therapeutic targets for hypertension, such as vaccines and microbiome-directed therapies, which may offer new options for patients with resistant hypertension.
Hypertension is one of the most prevalent cardiovascular diseases worldwide. However, in the population of resistant hypertension, blood pressure is difficult to control effectively. Moreover, antihypertensive drugs may have adverse effect currently. Hence, new therapeutic targets and treatments are needed to uncovered and exploited to control hypertension and its comorbidities. In the past, classical drug targets, such as the aldosterone receptor, aldosterone synthase, and ACE2/angiotensin 1-7/Mas receptor axis, have been investigated. Recently, vaccines and drugs targeting the gastrointestinal microbiome, which represent drug classes, have also been investigated for the management of blood pressure. In this review, we summarized current knowledge on classical and new drug targets and discussed the potential utility of new drugs in the treatment of hypertension.
Gao et al. (Wed,) conducted a review in Hypertension. New drug targets for hypertension was evaluated. Classical and emerging therapeutic targets for hypertension, including the aldosterone pathway, vaccines, and the gastrointestinal microbiome, offer potential utility for blood pressure management.